Egypt Dermatological Therapeutics Market Analysis Report 2022 to 2030

Egypt Dermatological Therapeutics Market Analysis

$ 3999

Egypt Dermatological Therapeutics Market is at around $0.12 Bn in 2023 and is projected to reach $0.23 Bn in 2030, exhibiting a CAGR of 10.10% during the forecast period. The factors driving the expansion of the market are rising awareness, the prevalence of skin disorders, and advancements in treatment technologies. The market is dominated by key players like Egyptian International Pharmaceutical Co. (EPICO), Almirall SA, Pfizer Inc., GlaxoSmithKline Plc, AbbVie Inc., Amgen Inc., Novartis AG, Roche, Sanofi, Bayer, and Johnson & Johnson.

ID: IN10EGPH035 CATEGORY: Pharmaceuticals GEOGRAPHY: Egypt AUTHOR: Aneri Parekh

Buy Now

Egypt Dermatological Therapeutics Market Executive Summary

Egypt Dermatological Therapeutics Market is at around $0.12 Bn in 2023 and is projected to reach $0.23 Bn in 2030, exhibiting a CAGR of 10.10% during the forecast period.

Egypt Dermatological Therapeutics explores how dermatological care is developing in Egyptian medical practices. It covers the range of approaches used in Egypt to support skin health and well-being, from treating common skin disorders to exploring cutting-edge therapeutic methods.

Growing skin health consciousness and the prevalence of dermatological illnesses are fueling Egypt's market for dermatological therapeutics, which is expanding steadily. To increase their market position, major firms are concentrating on creative product creation and tactical alliances. The market is expanding as a result of an increase in the demand for cosmetic dermatology operations.

By 2023, the worldwide market for dermatological treatments brought in $40.94 Bn, a significant rise over the year before. Modern production techniques and low-cost technology are driving this industry change. The market for dermatological treatments has grown and expanded as a result of the dynamic combination of financial assistance, innovation, and accessibility.

EIPICO is a prominent pharmaceutical enterprise in Egypt, with a notable market share of 15-20% in the dermatological therapies sector. With a wide range of dermatological solutions, EIPICO can treat several skin issues, including fungus infections, psoriasis, acne, and eczema. These include both oral drugs, topical lotions, and ointments.

Egypt dermatological therapeutics market

Market Dynamics

Market Growth Drivers:

Growing knowledge: The availability of cutting-edge dermatological therapies and the population's growing knowledge of skin health issues are propelling market expansion. Demand for dermatological therapies is rising as a result of public education campaigns led by pharmaceutical corporations and medical practitioners.

Frequency of Skin Disorders: The need for dermatological therapies is greatly impacted by the incidence of skin conditions such as psoriasis, acne, eczema, and skin cancer. Effective therapies are becoming more and more necessary as the prevalence of these illnesses rises.

Technological Developments in Treatment: The launch of novel and cutting-edge dermatological remedies, such as inventive drugs, topical solutions, and surgical techniques, are driving the market. In the realm of dermatology, ongoing research and development efforts result in the introduction of innovative treatments.

Market Restraints:

Economic Factors: Consumer spending on healthcare, especially dermatological therapies, can be influenced by factors such as inflation, unemployment, and general economic stability.

Healthcare Infrastructure: The development of the dermatological therapeutics market may be impacted by Egypt's current level of healthcare infrastructure, which includes the availability of dermatologists, clinics, and cutting-edge treatment facilities.

Regulatory Environment: The market may be impacted by strict regulations or by delays in the clearance of innovative dermatological medications or therapies. Market dynamics may also be impacted by changes in rules.

Healthcare Policies and Regulatory Landscape

The Egyptian Drug Authority (EDA), a pharmaceutical regulatory body under the Egyptian Ministry of Health (MOH), is responsible for guaranteeing the efficacy and safety of pharmaceutical goods to safeguard the public's health. To lawfully sell pharmaceuticals in Egypt, applicants must provide the Egyptian Drug Authority with adequate information from each part attesting to the product's safety and effectiveness for the uses indicated in the recommended labeling. Because of the intricate web of documents, departments, and procedures involved, applicants may be trapped in the bureaucracy and ambiguity. It frequently takes the expertise of local specialists who are familiar with the peculiarities and protocols of the nation to successfully navigate this bureaucratic labyrinth.

Competitive Landscape

Key Players:

Egyptian International Pharmaceutical Co. (EPICO)
Almirall SA
Pfizer Inc.
GlaxoSmithKline Plc.
AbbVie Inc.
Amgen Inc.
Novartis AG
Roche
Sanofi
Bayer
Johnson & Johnson

1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share

4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment

6. Methodology and Scope

Egypt Dermatological Therapeutics Market Segmentation

By Type

Prescription-based Drugs
Over-the-counter Drugs

By Disease

Alopecia
Herpes
Psoriasis
Rosacea
Skin Cancer
Acne
Atopic Dermatitis
Vitiligo
Hidradenitis
Other Applications

By Drug Class

Anti-infectives
Corticosteroids
Anti-acne
Calcineurin Inhibitors
Retinoids
Other Drug Classes

By Route of Administration

Topical Administration
Oral Administration
Parenteral Administration

Methodology for Database Creation

Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.

Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.

How Do We Get It?

Our database is created and maintained through a combination of secondary and primary research methodologies.

1. Secondary Research

With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:

Analyzing historical proprietary data collected from multiple projects.
Regularly updating our existing data sets with new findings and trends.
Ensuring data consistency and accuracy through rigorous validation processes.

With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:

Searching through academic conferences, published research, citations, and social media platforms
Collecting and compiling diverse data to build a comprehensive and detailed database
Continuously updating our database with new information to ensure its relevance and accuracy

2. Primary Research

To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:

Collaborating with local healthcare providers, hospitals, and clinics to gather real-time data.
Conducting surveys, interviews, and field studies to collect fresh data directly from the source.
Continuously refreshing our database to ensure that the information remains current and reliable.
Validating secondary data through cross-referencing with primary data to ensure accuracy and relevance.

Combining Secondary and Primary Research

By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:

Merging historical data from secondary research with real-time data from primary research.
Conducting thorough data validation and cleansing to remove inconsistencies and errors.
Organizing data into a structured format that is easily accessible and usable for various applications.
Continuously monitoring and updating the database to reflect the latest developments and trends in the healthcare field.

Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.